Bio Conscious Technologies Inc.
Pardiss Danaei has a strong background in machine learning and deep learning, with experience in both industry and academia. In their most recent role as Director of Machine Learning at Bio Conscious Technologies Inc., Pardiss is leading the machine learning team. Prior to this, they worked as a Machine Learning Engineer at the same company.
Before joining Bio Conscious Technologies, Pardiss worked at The University of British Columbia as a Graduate Research Assistant. In this role, they conducted research on machine learning and deep learning frameworks for medical image analysis, specifically focused on segmentation, localization, and identification of medical images. They also developed a deep learning framework for accurate vertebrae localization and identification.
During their time as a Deep Learning Intern at The University of British Columbia, Pardiss collaborated with the RCL lab and engineered a novel method to localize and label the human vertebrae in spine MR volumes. This work was published in The IEEE International Symposium on Biomedical Imaging (ISBI) 2019.
Overall, Pardiss has a diverse range of experience in machine learning, deep learning, and medical image analysis.
Pardiss Danaei's education history includes a Bachelor of Applied Science (BASc) degree in Electrical and Computer Engineering from The University of British Columbia, which was obtained between 2012 and 2017. Following this, Pardiss pursued a Master of Engineering (MEng) degree in Biomedical Engineering, specializing in an AI/Machine Learning & Deep Learning field, at the same institution from 2017 to 2018. Finally, Pardiss completed a Master of Applied Science (MASc) degree in Biomedical Engineering with a focus on AI/Machine Learning & Deep Learning from The University of British Columbia between 2017 and 2020.
This person is not in any teams
Bio Conscious Technologies Inc.
Bio Conscious is a health analytics company that has developed novel AI technology to predict and prevent adverse medical events leading to improved patient health, increased physician effectiveness, and reduced healthcare costs. Our approach is to proactively identify and predict the onset of disease states to avoid complications and furtherdisease progression. Our current focus is diabetes and related chronic diseases, an affliction affecting over 420 million globally. However, our technology platform is applicable to many other areas of healthcare.Our products and technology operate at the intersection of connected medical devices, remote monitoring, and the explosion of diabetes and related chronic disease. As these areas come together, cloud based interfaces make medical intervention achievable earlier in the disease progression and helps avoid complications, i.e. Prevention as a Service *TM*.